Head-to-head evidence
Cemsidomide vs Pomalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Cemsidomide
Developed by C4 Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07280013 (registry estimate)
Pomalidomide
Marketed by Bristol-Myers Squibb
NCT01311687 · Phase 3 · completed
This was a large, randomized 2:1 active-controlled trial involving 302 participants assigned to pomalidomide plus low-dose dexamethasone and 153 assigned to high-dose dexamethasone, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, progression-free survival, was met: median PFS was 15.7 versus 8.0 weeks, with HR 0.45 (95% CI 0.35–0.59; p<0.001), supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05581875 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · Pomalidomide's landscape